reference/26196844

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26196844

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	4541
issn	1527-7755 0732-183X
issueIdentifier	27
pageRange	4536-4541
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	4536
bibliographicCitation	Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009 Sep 20;27(27):4536–41. doi: 10.1200/jco.2008.21.3033. PMID: 19687332.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a5957183b5d7d525f9d5bbdcc1b2c05 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc58b3ab12b1ffc6a87959440c0642fe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2fd3ba51a41e378854123439d3f2068f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b896b23bb4437d0c5dfee35bdb3367ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d0d6fc1da4b8894dac49f18f68fb1af1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_21359ae1a8c82720e03d41b991e14646 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a9a0f0357851d2311edeefe24251118 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffe149f4d1e31a3c07ec0e3fdec0a4cc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c6a75b58454074610d14115a4243ed1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_08ca4369c964c7919f40305bb4f70f9f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_93256a103e4376ce9cb2203aa013ea5a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3cf3d3b12e1117742bac52414cd26198 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c15bc3f381d60afab4e9447539c03bae http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60b792a60aca196a5a808602c3442551 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8dd1b91dad7457e791723ed0258855d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0758-9666 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_70059dafa7e519ec7227c2600da405a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_405242326695a4296b2dc9f9fc93b48a
date	2009-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/19687332 https://doi.org/10.1200/jco.2008.21.3033
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/1527-7755
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0029863 http://id.nlm.nih.gov/mesh/M0011171 http://id.nlm.nih.gov/mesh/M000602394
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D007166Q000008 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D020123Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D001943Q000556 http://id.nlm.nih.gov/mesh/D000068338 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D020123Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7353 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9309 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3453a5d8c5baa0d0e6382e0d81213cb6 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6d00df506eed78175933b5ecde287c64 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_bcd6f21312d21a5cf3f0a82f59d9ac97 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129138006 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248184126

Total number of triples: 76.